Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
The latest update is out from Livzon Pharmaceutical Group ( (HK:1513) ).
Livzon Pharmaceutical Group has announced the acquisition of a 64.81% stake in a Vietnamese company, marking a significant expansion in its international operations. The transaction, valued at approximately RMB1.587 billion, will see the target company become an indirect non-wholly owned subsidiary, with its financial results consolidated into Livzon’s financial statements. This acquisition, classified as a discloseable transaction under Hong Kong Listing Rules, highlights Livzon’s strategic move to strengthen its market presence in Vietnam, potentially enhancing its competitive positioning in the pharmaceutical industry.
The most recent analyst rating on (HK:1513) stock is a Sell with a HK$24.00 price target. To see the full list of analyst forecasts on Livzon Pharmaceutical Group stock, see the HK:1513 Stock Forecast page.
More about Livzon Pharmaceutical Group
Average Trading Volume: 1,090,004
Technical Sentiment Signal: Buy
Current Market Cap: HK$31.19B
For detailed information about 1513 stock, go to TipRanks’ Stock Analysis page.